The Role Of Maqui Berry Extract In Dry Eye Disease And Ocular Surface Inflammation.
Published 2023 - 41st Congress of the ESCRS
Reference: FP26.01 | Type: Free paper | DOI: 10.82333/kk1d-2m88
Authors: Riddhi Raichura 1 , Rohit Shetty 1 , Gairik Kundu 1 , Pooja Khamar* 2 , Swaminathan Sethu 3
1Cornea and Refractive,Narayana Nethralaya,Bengaluru,India, 2Cataract and Refractive,Narayana Nethralaya,Bengaluru,India, 3GROW Lab,Narayana Nethralaya,Bengaluru,India
Purpose
The aim of this study is to investigate the effects of Maqui berry extract (30mg) twice/day in improving signs and symptoms of dry eye disease (DED) along with ocular surface inflammation in patients with DED, with the aid of dry eye parameters and tear biomarkers profile as compared with patients treated with placebo (PLC).
Setting
Narayana Nethralaya , Bengaluru, Karnataka, India
Methods
20 patients were randomly assigned to Maqui berry extract (MBE) (30mg) twice/day or a PLC. DED parameters including Schirmer’s test 1 (ST1), tear film break-up time (TBUT), ocular surface disease index (OSDI), and corneal staining were assessed before treatment, and 2 months post-treatment. Tear fluid samples before and after treatment from a sub-set of these patients were collected from the study subjects using sterile Schirmer’s strips and the levels of interleukin (IL)-1β, IL-10, IL-6, IL-17A, tumor necrosis factor-α (TNFα), matrix metalloproteinase-9 (MMP9), soluble intercellular adhesion molecule-1 (sICAM1), and vascular endothelial growth factor-A (VEGF-A) were measured using a microfluidic cartridge-based multiplex ELISA.
Results
The Maqui berry extract group demonstrated a significant (P<0.05) decrease in OSDI scores along with a significant increase in Schirmer's test 1 compared to the placebo group. No significant change in TBUT and corneal staining was observed between the two study groups. The pro-inflammatory factors such as IL-1β, IL-6, IL-17A, TNFα, and MMP9 were observed to be significantly reduced, along with a significant increase in IL-10 levels following treatment in the MBE group compared with the PLC group.
Conclusions
Consumption of Maqui berry extract (30mg) twice/day for a period of 2 months resulted in the improvement and resolution of DED signs and symptoms, along with a reduction in ocular surface inflammation based on Dry eye parameters and Tear biomarker profile. It can prove to be a useful option in the form of oral supplementation in patients with Dry eye disease to enhance and improve the ocular surface health.